CLINICAL TRIALS PROFILE FOR VANCERIL DOUBLE STRENGTH

All Clinical Trials for VANCERIL DOUBLE STRENGTH

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00489203 ↗	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Completed	Fred Hutchinson Cancer Research Center	Phase 2	2007-04-01	RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer. PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell transplant for hematologic cancer.

Clinical Trial Conditions for VANCERIL DOUBLE STRENGTH

Condition Name

Condition Name for VANCERIL DOUBLE STRENGTH
Intervention	Trials
Stage I Childhood Hodgkin Lymphoma	1
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma	1
Stage III Multiple Myeloma	1
Primary Myelofibrosis	1

Condition MeSH

Condition MeSH for VANCERIL DOUBLE STRENGTH
Intervention	Trials
Leukemia, Hairy Cell	1
Neoplasms, Plasma Cell	1
Lymphoma, Large B-Cell, Diffuse	1
Leukemia, Myeloid, Acute	1

Clinical Trial Locations for VANCERIL DOUBLE STRENGTH

Trials by Country

Trials by Country for VANCERIL DOUBLE STRENGTH
Location	Trials
United States	2

Trials by US State

Trials by US State for VANCERIL DOUBLE STRENGTH
Location	Trials
Washington	1
New Jersey	1

Clinical Trial Progress for VANCERIL DOUBLE STRENGTH

Clinical Trial Phase

Clinical Trial Phase for VANCERIL DOUBLE STRENGTH
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for VANCERIL DOUBLE STRENGTH
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for VANCERIL DOUBLE STRENGTH

Sponsor Name

Sponsor Name for VANCERIL DOUBLE STRENGTH
Sponsor	Trials
Fred Hutchinson Cancer Research Center	1

Sponsor Type

Sponsor Type for VANCERIL DOUBLE STRENGTH
Sponsor	Trials
Other	1

Last updated: June 2, 2026

Vanceril Double Strength clinical trials update, market analysis and projection (2024–2030)

No complete, decision-grade patent-and-regulatory dossier is available in the provided context for “VANCERIL DOUBLE STRENGTH” to support a high-stakes clinical-trials update, market sizing, and 2030 projection.

What clinical trials exist for Vanceril Double Strength and what are the latest updates?

Answer: Insufficient verified data in the provided context to compile a clinical-trials timeline, study identifiers, endpoints, recruitment status, and results.

Which registry entries (ClinicalTrials.gov / EU CTR) should be used for Vanceril Double Strength?

Answer: Not provided.

What patient populations and endpoints define efficacy and safety in the key trials?

Answer: Not provided.

Is Vanceril Double Strength being tested under an FDA pathway (505(b)(2), 505(j), or 351)?

Answer: Not provided.

How big is the Vanceril Double Strength market and what drivers set demand?

Answer: Insufficient verified data in the provided context to compute TAM/SAM/SOM, pricing assumptions, channel mix, and demand drivers.

What is the therapeutic area and target indication for Vanceril Double Strength?

Answer: Not provided.

What comparable products and competitive dynamics matter most?

Answer: Not provided.

What reimbursement and payer factors influence adoption?

Answer: Not provided.

When does Vanceril Double Strength face generic or biosimilar entry risk?

Answer: Not provided. Patent, exclusivity, Orange Book listing, and litigation status are not included in the provided context.

What patents protect Vanceril Double Strength (active ingredient, formulation, method of use)?

Answer: Not provided.

What is the Orange Book status and listed expiration dates?

Answer: Not provided.

Are there Paragraph IV challenges or other FDA exclusivity litigation?

Answer: Not provided.

What market projection to 2030 is consistent with FDA, patent, and competitive timelines?

Answer: Not provided. A projection requires verified assumptions on regulatory exclusivity, expected generic entry timing, competitive adoption curves, and pricing trends, none of which are present in the provided context.

Base, upside, and downside scenarios

Answer: Not provided.

Sensitivity analysis inputs (price erosion, volume growth, channel penetration)

Answer: Not provided.

Which companies compete with Vanceril Double Strength and how do their product curves compare?

Answer: Not provided.

How strong is the patent estate for Vanceril Double Strength?

Answer: Not provided.

What generic entry risks exist for Vanceril Double Strength by geography?

Answer: Not provided.

What formulation or manufacturing IP barriers could slow generic development?

Answer: Not provided.

Key Takeaways

• Decision-grade clinical-trials update and market forecast for Vanceril Double Strength cannot be produced from the information provided.
• Patent, Orange Book/FDA status, and litigation milestones are required to map exclusivity and generic-entry risk into a credible 2024–2030 projection, but are not included in the provided context.

FAQs

1. What is the FDA regulatory status of Vanceril Double Strength (NDA/ANDA/505(b)(2))?
2. What is listed in the Orange Book for Vanceril Double Strength, and when do patents expire?
3. Are there any ongoing Paragraph IV litigations tied to Vanceril Double Strength?
4. What endpoints and results drive efficacy for Vanceril Double Strength in late-stage trials?
5. How quickly would volume and pricing likely erode after generic launch for Vanceril Double Strength?

References

No sources were provided in the prompt to cite.